824960-82-9 Usage
Description
(2E)-3-(4-BROMO-3-NITRO-PHENYL)-ACRYLIC ACID is a derivative of acrylic acid with the molecular formula C9H6BrNO4, featuring a 3-nitro-4-bromo-phenyl group. This yellow to orange crystalline solid exhibits a high melting point and is sparingly soluble in water, making it a valuable intermediate in the synthesis of various organic compounds.
Uses
Used in Pharmaceutical Industry:
(2E)-3-(4-BROMO-3-NITRO-PHENYL)-ACRYLIC ACID is used as an intermediate in the synthesis of pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, (2E)-3-(4-BROMO-3-NITRO-PHENYL)-ACRYLIC ACID serves as an intermediate for the production of agrochemicals, aiding in the creation of pesticides and other agricultural chemicals.
Used in Materials Science:
(2E)-3-(4-BROMO-3-NITRO-PHENYL)-ACRYLIC ACID is utilized in materials science for its unique structural and electronic properties, potentially leading to advancements in material development and applications.
Used in Organic Electronics:
(2E)-3-(4-BROMO-3-NITRO-PHENYL)-ACRYLIC ACID also has potential applications in organic electronics, where its structural and electronic characteristics can be harnessed for the development of novel electronic devices and components.
Check Digit Verification of cas no
The CAS Registry Mumber 824960-82-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,2,4,9,6 and 0 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 824960-82:
(8*8)+(7*2)+(6*4)+(5*9)+(4*6)+(3*0)+(2*8)+(1*2)=189
189 % 10 = 9
So 824960-82-9 is a valid CAS Registry Number.
824960-82-9Relevant articles and documents
Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of polo-like kinase 1 (MLN0905)
Duffey, Matthew O.,Vos, Tricia J.,Adams, Ruth,Alley, Jennifer,Anthony, Justin,Barrett, Cynthia,Bharathan, Indu,Bowman, Douglas,Bump, Nancy J.,Chau, Ryan,Cullis, Courtney,Driscoll, Denise L.,Elder, Amy,Forsyth, Nancy,Frazer, Jonathan,Guo, Jianping,Guo, Luyi,Hyer, Marc L.,Janowick, David,Kulkarni, Bheemashankar,Lai, Su-Jen,Lasky, Kerri,Li, Gang,Li, Jing,Liao, Debra,Little, Jeremy,Peng, Bo,Qian, Mark G.,Reynolds, Dominic J.,Rezaei, Mansoureh,Scott, Margaret Porter,Sells, Todd B.,Shinde, Vaishali,Shi, Qiuju Judy,Sintchak, Michael D.,Soucy, Francois,Sprott, Kevin T.,Stroud, Stephen G.,Nestor, Michelle,Visiers, Irache,Weatherhead, Gabriel,Ye, Yingchun,Damore, Natalie
, p. 197 - 208 (2012/03/10)
This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.
